Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 5:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: control formulation Clear all
Completed Phase 3 Interventional Results available

Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours

NCT00353496
View directory record Official record
Conditions
Endocrine Tumors
Interventions
lanreotide (Autogel formulation), Placebo
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
8
States / cities
Los Angeles, California • Iowa City, Iowa • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Sep 3, 2026, 5:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Comparing the Availability of AQ280 in the Body After Single Oral Doses of a Capsule Formulation Versus a Tablet for Oral Suspension Formulation

NCT07093008
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
AQ280 Capsule, AQ280 Tablet for Oral Suspension, Placebo Capsule, Placebo Tablet for Oral Suspension
Drug
Lead sponsor
AQILION AB
Industry
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 3, 2026, 5:39 PM EDT
Completed Phase 2 Interventional Results available

A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) For Treatment of Atopic Dermatitis

NCT02871479
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
SAN007 5% cream, Placebo, SAN007 10% cream
Drug
Lead sponsor
Santalis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Austin, Texas • Bryan, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2019 · Synced Sep 3, 2026, 5:39 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy Study of a New Formulation of Acetylcysteine Injection

NCT01118663
View directory record Official record
Conditions
Acetaminophen Overdose
Interventions
Acetadote EF (Ethylenediaminetetraacetic Acid (EDTA) - Free), Acetadote
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
14
States / cities
Phoenix, Arizona • Loma Linda, California • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2014 · Synced Sep 3, 2026, 5:39 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nutraceutical Supplement With Standardized Botanicals in Males With Thinning Hair

NCT05339958
View directory record Official record
Conditions
Hair Thinning
Interventions
Nutrafol® Men Hair Growth Nutraceutical, Placebo Supplement
Dietary Supplement · Other
Lead sponsor
Nutraceutical Wellness Inc.
Industry
Eligibility
21 Years to 55 Years · Male only
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
Manhattan Beach, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Sep 3, 2026, 5:39 PM EDT
Completed Phase 2 Interventional Results available

Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Multiple Oral Bedtime Doses of ORMD-0801 in Adult Patients With Type 2 Diabetes Mellitus (T2DM)

NCT01889667
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
ORMD-0801 Dose # 1, ORMD-0801 Dose # 2, Placebo
Drug
Lead sponsor
Oramed, Ltd.
Industry
Eligibility
20 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Sep 3, 2026, 5:39 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Various Respiratory Syncytial Virus (RSV) Pre-Fusion (preF)-Based Vaccine Formulations in Adults Aged 60 Years and Older

NCT05327816
View directory record Official record
Conditions
Respiratory Syncytial Virus-associated Lower Respiratory Tract Disease Prevention
Interventions
RSV preF-based Vaccine, Placebo
Biological · Drug
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
60 Years and older
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
11
States / cities
Long Beach, California • DeLand, Florida • Miami Lakes, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Sep 3, 2026, 5:39 PM EDT
Completed Phase 2 Interventional

Mazindol Controlled Release in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

NCT02808104
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
mazindol
Drug
Lead sponsor
NLS Pharmaceutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Newport Beach, California • Jacksonville, Florida • Marshfield, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Sep 3, 2026, 5:39 PM EDT
Completed Not applicable Interventional Results available

Foley Catheter Compared to the Foley Catheter Alone for Cervical Ripening

NCT03111316
View directory record Official record
Conditions
Cervical Ripening, Induction of Labor
Interventions
Cervidil 10 MG Vaginal Insert, Foley Catheter
Drug · Device
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Sep 3, 2026, 5:39 PM EDT
Terminated Phase 2 Interventional

Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.

NCT00117884
View directory record Official record
Conditions
Papillomavirus Infections
Interventions
851B
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
22
States / cities
Colton, California • San Diego, California • Colorado Springs, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2016 · Synced Sep 3, 2026, 5:39 PM EDT
Not yet recruiting Phase 2 Interventional

Clinical Study to Evaluate the Safety and the Efficacy of EscharEx Drug Product (EX-03 Formulation) and Its Placebo Compared to Collagenase, Non-surgical Standard of Care, in Patients With Venous Leg Ulcers

NCT06690177
View directory record Official record
Conditions
Venus Leg Ulcers
Interventions
EscharEx (EX-03), Placebo (Gel vehicle)
Drug
Lead sponsor
MediWound Ltd
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Carlsbad, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Sep 3, 2026, 5:39 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of the Irritation Potential of Sunscreen Products in Human Eyes

NCT02854137
View directory record Official record
Conditions
Sunscreening Agents
Interventions
BAY987521, Control
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 60 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Sep 3, 2026, 5:39 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Obesity, Oral Contraception, and Ovarian Suppression

NCT00827632
View directory record Official record
Conditions
Ovarian Suppression
Interventions
Low dose formulation, High dose formulation
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Sep 3, 2026, 5:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Investigation Of The Absorption And Pharmacokinetics Of A Single Dose Of A Controlled Release (CR) Pregabalin Tablet Following Various Sized Lunches As Compared To A Single Dose Of The Immediate Release (IR) Pregabalin Capsule In Healthy Volunteers

NCT01270815
View directory record Official record
Conditions
Healthy
Interventions
Pregabalin controlled release, 330 mg, 400 to 500 calories, Pregabalin controlled release, 330 mg, 600 to 750 calories, Pregabalin controlled release, 330 mg, 800 to 1000 calories, Pregabalin immediate release, 300 mg
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 21, 2021 · Synced Sep 3, 2026, 5:39 PM EDT
Not yet recruiting Not applicable Interventional

Safety and Tolerability of a Nutritional Formula Designed to Aid in Maintenance of Muscle During Periods of Caloric Restriction in Adults

NCT07447843
View directory record Official record
Conditions
Obesity & Overweight
Interventions
Redefine, Placebo
Dietary Supplement
Lead sponsor
Nature's Sunshine Products, Inc.
Industry
Eligibility
35 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Lehi, Utah
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 3, 2026, 5:39 PM EDT
Completed Phase 3 Interventional Results available

Efficacy Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail

NCT00443820
View directory record Official record
Conditions
Onychomycosis
Interventions
terbinafine, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 75 Years
Enrollment
526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
20
States / cities
Novato, California • Northglenn, Colorado • Melbourne, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2011 · Synced Sep 3, 2026, 5:39 PM EDT
Completed Phase 3 Interventional Results available

Multicenter Randomized Active-controlled Study to Investigate Efficacy & Safety of IV FCM in Pediatric Patients With IDA

NCT03523117
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
Ferric carboxymaltose, Ferrous Sulfate
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
16
States / cities
Little Rock, Arkansas • Doral, Florida • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Sep 3, 2026, 5:39 PM EDT
Not listed Not applicable Interventional

Effects on Glycemic Control of WBF-0031 in Subjects With Abnormal Glucose Tolerance

NCT04490460
View directory record Official record
Conditions
Abnormal Glucose Tolerance
Interventions
WBF-0031
Dietary Supplement
Lead sponsor
Eden Miller
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Bend, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Sep 3, 2026, 5:39 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Tolerability, Safety and Immunogenicity of MVX01 Pneumococcal Vaccine

NCT06337643
View directory record Official record
Conditions
Pneumococcal Vaccine
Interventions
MVX01, MVX01 Placebo
Biological
Lead sponsor
Matrivax Research and Development Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Savannah, Georgia • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Sep 3, 2026, 5:39 PM EDT
Completed Phase 3 Interventional

A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery

NCT05425056
View directory record Official record
Conditions
Complication of Renal Dialysis, End Stage Renal Disease, End Stage Kidney Disease, ESRD, Chronic Kidney Failure, Complication of Hemodialysis, Vascular Access Complication, Arteriovenous Fistula
Interventions
Sirolimus
Drug
Lead sponsor
Vascular Therapies, Inc.
Industry
Eligibility
65 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
17
States / cities
San Diego, California • Torrance, California • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Sep 3, 2026, 5:39 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study Testing Ketamine Sublingual Wafer After Wisdom Tooth Extraction

NCT02356965
View directory record Official record
Conditions
Pain
Interventions
Ketamine, Placebo (for Ketamine)
Drug
Lead sponsor
iX Biopharma Ltd.
Other
Eligibility
18 Years to 38 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Sep 3, 2026, 5:39 PM EDT
Completed Phase 2 Interventional

Randomized, Double-blind, Placebo Controlled Phase II Study to Examine the Effects of DAS181 in Healthy Adult Subjects With Laboratory Confirmed Influenza

NCT01037205
View directory record Official record
Conditions
Influenza
Interventions
DAS181 dry powder, formulation F02, Respitose ML006 (DMV-Fonterra)
Drug
Lead sponsor
Ansun Biopharma, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
42
States / cities
Carmichael, California • Chula Vista, California • La Mesa, California + 39 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2014 · Synced Sep 3, 2026, 5:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant Women

NCT03674177
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
GSK3888550A RSV Maternal vaccine formulation 1, GSK3888550A RSV Maternal vaccine formulation 2, GSK3888550A RSV Maternal vaccine formulation 3, Placebo (Normal Saline)
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
502 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Lenexa, Kansas • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Sep 3, 2026, 5:39 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and Older

NCT05639894
View directory record Official record
Conditions
Respiratory Syncytial Virus Immunization
Interventions
RSV vaccine candidate, Placebo
Biological · Other
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
865 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
25
States / cities
Huntsville, Alabama • Mesa, Arizona • Peoria, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 3, 2026, 5:39 PM EDT